Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2011

View Archived Issues

Sanofi-aventis presents highlights of first quarter of 2011

Novel tetracycline TP-2758 efficacious in models of urinary tract infections and pyelonephritis

New nicotinic acetylcholine alpha7 receptor agonists claimed

Novel agents for Gram-negative bacterial infections synthesized at Pfizer

Merck & Co. patents new inhibitors of Mdm2-p53 interaction

Cephalon begins phase I/II CEP-9722 trial in advanced solid tumors

Albany Medical School and Aegis Therapeutics join to develop peptide against breast cancer

Evotec achieves new milestone in Boehringer Ingelheim drug discovery alliance

AstraZeneca discloses preclinical data on AZD-5363, in phase I testing in solid tumors

VT-1129 shows benefit in model of cryptococcal meningitis

Pooled trial data show linaclotide improves symptoms of constipation

AZD-2066 reduces transient lower esophageal sphincter relaxations in healthy subjects

Concert Pharmaceuticals prepares new GABA(A) receptor modulators

New sepiapterin reductase inhibitors claimed

Pharmacyclics discloses new tyrosine-protein kinase BTK inhibitors

Gentium submits defibrotide MAA to EMA for hepatic VOD in stem cell transplant recipients

Phase III trial of istradefylline in Parkinson's disease meets primary endpoint

Roche seeks FDA and EMA approval for vemurafenib in metastatic melanoma

National Cancer Institute to sponsor phase I study of Reolysin in multiple myeloma

Results from Asian study of lurasidone in schizophrenia inadequate to support filing in Japan

Sosei gains Japanese rights to antifungal agent Loramyc from BioAlliance

Allos Therapeutics and Mundipharma to codevelop anticancer drug Folotyn

Takeda acquires exclusive rights to fomepizole in Japan from Paladin Labs

Swissmedic approves Novartis' Votubia for brain tumors associated with tuberous sclerosis

Galapagos commences second proof-of-mechanism phase I trial of GLPG-0778

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...